Loading...
The University of Chicago Header Logo
Keywords
Last Name
Institution

Comparative proteomic profiling of sera from patients with refractory multiple myeloma reveals potential biomarkers predicting response to bortezomib-based therapy.

Luczak M, Kubicki T, Rzetelska Z, Szczepaniak T, Przybylowicz-Chalecka A, Ratajczak B, Czerwinska-Rybak J, Nowicki A, Joks M, Jakubowiak A, Komarnicki M, Dytfeld D. Comparative proteomic profiling of sera from patients with refractory multiple myeloma reveals potential biomarkers predicting response to bortezomib-based therapy. Pol Arch Intern Med. 2017 06 30; 127(6):392-400.

View in: PubMed

collapse authors with profiles